A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.

Trial Details

NCT ID
NCT06783569
Phase
PHASE1
Sponsor
JiaRay Group
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • JR8603
Locations (sample)
  • Harbin, Heiljiang Province, China|45.75,126.65
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Patients who meet ALL the following inclusion criteria will be eligible to participate in the study:
  • ≥18 years of age.
  • Histologically confirmed, locally advanced, or metastatic solid tumor which has progressed on, or patients intolerant to, all standard therapy, or …
  • Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →